Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease.
SU2C’s first unprecedented television fundraising event aired simultaneously on the ABC, CBS and NBC networks in September 2008. An array of stars from film, TV, sports and journalism urged viewers to “Stand Up” and join the fight against cancer in memory of those we have lost to the disease, and in solidarity with those living with it. SU2C has produced four subsequent “roadblock” telecasts, in 2010, 2012, 2014 and 2016. The most recent telecast was carried on more than 60 broadcast and cable networks and streaming platforms in the U.S. and Canada.
Well over 800 actors, musicians, athletes, and public figures have volunteered their time in support of SU2C in these telecasts and in other awareness and social media activities. Musical performers have included Beyoncé, Céline Dion, Alicia Keys, Sheryl Crow, Stevie Wonder, Jennifer Hudson, Common, Dave Matthews, Coldplay, Taylor Swift and Tim McGraw. Celebrity participants have included Viola Davis, Tom Hanks, Pierce Brosnan, Halle Berry, Meryl Streep, Denzel Washington, Julia Roberts, Eric Stonestreet, Sally Field, Forest Whitaker, Reese Witherspoon, Ken Jeong, Sofia Vergara, George Clooney, Edward Norton, Emma Stone, Justin Timberlake, Jennifer Aniston, and Jon Hamm.
SU2C’s “signature” Dream Teams of scientists and doctors, from different disciplines and institutions, work together in synergistic and innovative groups. In addition, SU2C has forged new collaborations through its Convergence program, where clinical researchers work together with engineers and physicists. SU2C Catalyst® projects bring together academic researchers, funding, and compounds supplied by supporting pharmaceutical and diagnostic companies to accelerate cutting-edge clinical trials, often involving novel combinations of compounds. SU2C has formalized collaborations in Cancer Interception, which involves finding ways to actively intervene in the formation of cancers, rather than waiting to treat fully developed malignancies.
The Scientific Advisory Committee (SAC), a “blue ribbon panel,” provides guidance in developing the SU2C research portfolio. Chaired by Nobel Laureate Phillip A. Sharp, Ph.D., institute professor at the Massachusetts Institute of Technology and the Koch Institute for Integrative Cancer Research at MIT, the SAC involves approximately 25 other highly accomplished senior researchers and physician-scientists, as well as representatives of several national advocacy organizations. Working with its Joint Scientific subcommittees, the SAC has awarded grants to a total of 22 of SU2C’s signature Dream Teams, 9 additional Research Teams, as well as 46 Innovative Research Grant recipients. Grants have also been awarded for clinical trial projects under the innovative SU2C Catalyst® program, as well as multi-year awards to support collaboration between different SU2C researchers across teams.
The work of SU2C is supported by its scientific partner, the prestigious American Association for Cancer Research (AACR). AACR supports grants solicitation, contracting, administration and review across an array of Teams, the Innovative Research Grants, and many additional grants and awards.
Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, PhD, RN, has served as SU2C’s president and CEO since 2011
22 Dream Teams
16 Research Teams
10 SU2C Catalyst® Teams
180+ Clinical trials planned, underway or completed
9,000+ Patients participating in SU2C-supported clinical trials
SU2C research has substantively contributed to the FDA approval of five treatments